A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
Status:
Not yet recruiting
Trial end date:
2023-01-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effect of LY3437943 when administered
subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when
administered orally as a drug cocktail in obese participants. This study will last up to
approximately 25 weeks for each participant.